Sign in Subscribe
Pharmaceutical industry

OPTISON: A Breakthrough in Cardiac Ultrasound Contrast Imaging

Strategic Insights

— 1 min read

OPTISON, a state-of-the-art cardiac ultrasound contrast imaging agent, has made a significant impact on the medical community with its groundbreaking technology. Developed by Molecular Biosystems and marketed by Mallinckrodt, OPTISON has been the subject of over a dozen presentations at the 1999 annual meeting of the American College of Cardiology (ACC). These presentations highlight the agent's potential in improving diagnosis and treatment of heart disease.

Key Takeaways:

  • **Widespread adoption:** OPTISON is currently being used in over 1,600 hospitals and cardiology group practices throughout the United States, Germany, Austria, Spain, and the United Kingdom.
  • **Improved diagnosis:** OPTISON has been shown to improve diagnostic accuracy in technically difficult patients, with a 20% increase in image quality and wall segment visualization.
  • **Increased confidence in interpretation:** Studies have demonstrated that OPTISON enhances image quality, allowing physicians to make more confident interpretations.
  • **New insights into coronary endothelium:** Researchers have used OPTISON to investigate the mechanisms of albumin microbubble adhesion to coronary endothelium, offering new insights into cardiovascular disease.
  • **Myocardial perfusion analysis:** OPTISON has been evaluated in the assessment of myocardial perfusion defects, providing valuable information for clinical decision-making.
  • **Real-time detection of myocardial perfusion defects:** Researchers have successfully used OPTISON to detect perfusion defects in real-time, improving diagnosis and treatment.
  • **Quantitative analysis of coronary vasculopathy:** OPTISON has been used to analyze coronary vasculopathy in patients with Fabry disease, providing valuable insights into vascular disease.

Statistics:

  • **Annual cardiac ultrasound procedures:** Over 15 million cardiac ultrasound procedures are performed annually in the United States and Europe.
  • **Technically difficult exams:** Physicians estimate that up to 20% of these procedures are technically difficult and provide less than optimal information.
  • **Number of presentations:** OPTISON has been the subject of over a dozen presentations at the 1999 ACC scientific session.
  • **Number of hospitals and practices:** OPTISON is currently being used in over 1,600 hospitals and cardiology group practices.

Sources:

  • PRNewswire, "Mallinckrodt Inc. and Molecular Biosystems, Inc. Announce OPTISON, Advanced-Generation Cardiac Ultrasound Contrast Imaging Agent Featured at American College of Cardiology"
  • American College of Cardiology, "Scientific Session Abstracts"

Read more